Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Weisman

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
ACS Chemical Neuroscience|March 20, 2024
Targeting Neuroinflammation by Pharmacologic Downregulation of Inflammatory Pathways Is Neuroprotective in Protein Misfolding DisordersSydney J Risen, Sean W Boland, Sadhana Sharma, et al.
Rheumatology (Oxford, England)|November 18, 2004
Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severityL Jin, M Weisman, G Zhang, et al.
Arthritis and Rheumatism|February 20, 1999
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extensionD E Furst, H Lindsley, B Baethge, et al.
Annals of the Rheumatic Diseases|September 24, 2016
Treat-to-target (T2T) recommendations for goutU Kiltz, J Smolen, T Bardin, et al.
Arthritis and Rheumatism|November 11, 1999
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosisP J Clements, W K Wong, E L Hurwitz, et al.
The Journal of Rheumatology|April 1, 2000
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritisL W Moreland, D P McCabe, J R Caldwell, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
ACS Chemical Neuroscience|March 20, 2024
Targeting Neuroinflammation by Pharmacologic Downregulation of Inflammatory Pathways Is Neuroprotective in Protein Misfolding DisordersSydney J Risen, Sean W Boland, Sadhana Sharma, et al.
Rheumatology (Oxford, England)|November 18, 2004
Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severityL Jin, M Weisman, G Zhang, et al.
Arthritis and Rheumatism|February 20, 1999
Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extensionD E Furst, H Lindsley, B Baethge, et al.
Annals of the Rheumatic Diseases|September 24, 2016
Treat-to-target (T2T) recommendations for goutU Kiltz, J Smolen, T Bardin, et al.
Arthritis and Rheumatism|November 11, 1999
Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosisP J Clements, W K Wong, E L Hurwitz, et al.
The Journal of Rheumatology|April 1, 2000
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritisL W Moreland, D P McCabe, J R Caldwell, et al.
Rheumatology (Oxford, England)|June 27, 2001
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trialD E Furst, P J Clements, W K Wong, et al.
Arthritis and Rheumatism|November 18, 2000
Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trialP J Clements, E L Hurwitz, W K Wong, et al.
Arthritis and Rheumatism|March 27, 2001
The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trialP J Clements, W K Wong, E L Hurwitz, et al.
Annals of Internal Medicine|June 3, 2000
Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trialJ R Seibold, J H Korn, R Simms, et al.
Pageof 14